Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 8221 results

  1. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  2. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

    In development Reference number: GID-TA11669 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  3. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

    Technology appraisal guidance
    In development

  4. ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)

    In development Reference number: GID-TA11850 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  5. Teprotumumab for treating thyroid eye disease [ID6432]

    In development Reference number: GID-TA11531 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  7. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  8. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  9. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  10. Insulin efsitora alfa for treating type 2 diabetes ID6499

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  11. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development Reference number: GID-TA10638 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Ianalumab for treating active Sjogren's syndrome [ID6634]

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

    In development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Infant, children and young people's experience of health care

    Awaiting development Reference number: GID-QS10102 Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Gambling

    Awaiting development Reference number: GID-QS10099 Expected publication date: TBC

    Quality standard
    Awaiting development